Boyer, D. S., Kaiser, P. K., Magrath, G. N., Brady, K., Edwards, S., Tanzer, D. J., & Heier, J. S. (2022). The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study. Ophthalmic surgery, lasers & imaging retina, 53(10), 553. https://doi.org/10.3928/23258160-20220923-02
Style de citation ChicagoBoyer, David S., Peter K. Kaiser, George N. Magrath, Kerrie Brady, Scott Edwards, David J. Tanzer, et Jeffrey S. Heier. "The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study." Ophthalmic Surgery, Lasers & Imaging Retina 53, no. 10 (2022): 553. https://dx.doi.org/10.3928/23258160-20220923-02.
Style de citation MLABoyer, David S., et al. "The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study." Ophthalmic Surgery, Lasers & Imaging Retina, vol. 53, no. 10, 2022, p. 553.